Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.

Vandana Batra Minu Samanta Mehran Makvandi David Groff Paul Martorano Jimmy Elias Pietro Ranieri Matthew Tsang Catherine Hou Yimei Li Bruce R Pawel Daniel Martinez Ganesan Vaidyanathan Sean Carlin Daniel A Pryma John M Maris

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

[211At]MABG has significant survival advantage in disseminated models of neuroblastoma. An alpha particle emitting radiopharmaceutical may be effective against microscopic disseminated disease, warranting clinical development.

Keyphrases

quantum dots
cell therapy
bone marrow
free survival
energy transfer